Orchard Therapeutics shares
ORTX,
nearly doubled, to $15.79, after agreeing to be purchased by Japan’s Kyowa Kirin
4151,
for at least $16 per share in cash, plus an additional contingent value right of $1 per share. The total consideration will be as much as $478 million. London-based Orchard Therapeutics uses a patient’s own stem cells to produce therapies.
Read the full article here
